Pancreatic neuroendocrine tumor since 2011 with hepatic metastatic resection July 2015. ABDOMEN:LIVER, BILIARY TRACT: Posttreatment changes of segment 8. There is very faint ill-defined reticular enhancement superior to the cavity (series 1403/71) which demonstrates no abnormal restricted diffusion or T2-weighted signal hyperintensity, likely treatment related. Nonenhancing hypointense focus in segment 3 of the liver is unchanged. The liver is otherwise normal in size, signal intensity and enhancement without biliary ductal dilatation or vascular abnormality.Cholelithiasis without cholecystitis.SPLEEN: Status post splenectomy.PANCREAS: Status post distal pancreatectomy without a suspicious lesion or pancreatic ductal dilatation.ADRENAL GLANDS: No significant abnormality noted.KIDNEYS, URETERS: No significant abnormality noted.RETROPERITONEUM, LYMPH NODES: No significant abnormality noted.BOWEL, MESENTERY: No significant abnormality noted.BONES, SOFT TISSUES: No significant abnormality noted.OTHER: No significant abnormality noted.
Stable post-treatment changes of segment 8 with marginal likely treatment-related faint enhancement. No suspicious liver lesion. 